In the last trading session, 1.12 million Bicara Therapeutics Inc (NASDAQ:BCAX) shares changed hands as the company’s beta touched 0. With the company’s per share price at $11.50 changed hands at $0.47 or 4.26% during last session, the market valuation stood at $627.17M. BCAX’s last price was a discount, traded about -144.26% off its 52-week high of $28.09. The share price had its 52-week low at $7.80, which suggests the last value was 32.17% up since then.

Bicara Therapeutics Inc (NASDAQ:BCAX) trade information

Instantly BCAX was in green as seen at the end of in last trading. With action 24.32%, the performance over the past five days has been green. The company’s shares are showing year-to-date downside of -33.98%, with the 5-day performance at 24.32% in the green. However, in the 30-day time frame, Bicara Therapeutics Inc (NASDAQ:BCAX) is -3.28% down.

The consensus price target for the stock as assigned by Wall Street analysts is 28, meaning bulls need an upside of 58.93% from its current market value. According to analyst projections, BCAX’s forecast low is 8 with 48 as the target high. To hit the forecast high, the stock’s price needs a -317.39% plunge from its current level, while the stock would need to tank 30.43% for it to hit the projected low.

The estimates for the next quarter sales put growth at 0.00%.

The 2025 estimates are for Bicara Therapeutics Inc earnings to increase by 42.88%, but the outlook for the next 5-year period is at 11.95% per year.

BCAX Dividends

Bicara Therapeutics Inc is expected to release its next quarterly earnings report in July.

Among Mutual Funds, the top two as of Mar 31, 2025 were Fidelity Select Portfolios-Health Care Portfolio and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund . With 700.0 shares estimated at $8.05 million under it, the former controlled 1.28% of total outstanding shares. On the other hand, VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund held about 1.17% of the shares, roughly 636.55 shares worth around $7.32 million.